These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
271 related articles for article (PubMed ID: 23216250)
21. Cold-shock domain family member YB-1 expression in endometrium and endometriosis. Silveira CG; Krampe J; Ruhland B; Diedrich K; Hornung D; Agic A Hum Reprod; 2012 Jan; 27(1):173-82. PubMed ID: 22095791 [TBL] [Abstract][Full Text] [Related]
22. Y-box binding protein, YB-1, as a marker of tumor aggressiveness and response to adjuvant chemotherapy in breast cancer. Huang J; Tan PH; Li KB; Matsumoto K; Tsujimoto M; Bay BH Int J Oncol; 2005 Mar; 26(3):607-13. PubMed ID: 15703814 [TBL] [Abstract][Full Text] [Related]
25. The contribution of tumour-derived exosomes to the hallmarks of cancer. Meehan K; Vella LJ Crit Rev Clin Lab Sci; 2016; 53(2):121-31. PubMed ID: 26479834 [TBL] [Abstract][Full Text] [Related]
26. Autophagy signaling in cancer and its potential as novel target to improve anticancer therapy. Moretti L; Yang ES; Kim KW; Lu B Drug Resist Updat; 2007; 10(4-5):135-43. PubMed ID: 17627865 [TBL] [Abstract][Full Text] [Related]
27. The transcriptional induction of PIK3CA in tumor cells is dependent on the oncoprotein Y-box binding protein-1. Astanehe A; Finkbeiner MR; Hojabrpour P; To K; Fotovati A; Shadeo A; Stratford AL; Lam WL; Berquin IM; Duronio V; Dunn SE Oncogene; 2009 Jun; 28(25):2406-18. PubMed ID: 19430491 [TBL] [Abstract][Full Text] [Related]
28. Prognostic markers and putative therapeutic targets for hepatocellular carcinoma. Frau M; Biasi F; Feo F; Pascale RM Mol Aspects Med; 2010 Apr; 31(2):179-93. PubMed ID: 20176048 [TBL] [Abstract][Full Text] [Related]
32. Increased nuclear localization of transcription factor Y-box binding protein 1 accompanied by up-regulation of P-glycoprotein in breast cancer pretreated with paclitaxel. Fujita T; Ito K; Izumi H; Kimura M; Sano M; Nakagomi H; Maeno K; Hama Y; Shingu K; Tsuchiya S; Kohno K; Fujimori M Clin Cancer Res; 2005 Dec; 11(24 Pt 1):8837-44. PubMed ID: 16361573 [TBL] [Abstract][Full Text] [Related]
34. 14-3-3 zeta as novel molecular target for cancer therapy. Matta A; Siu KW; Ralhan R Expert Opin Ther Targets; 2012 May; 16(5):515-23. PubMed ID: 22512284 [TBL] [Abstract][Full Text] [Related]
35. Y box binding protein 1 (YB-1) oncoprotein at the hub of DNA proliferation, damage and cancer progression. Sangermano F; Delicato A; Calabrò V Biochimie; 2020 Dec; 179():205-216. PubMed ID: 33058958 [TBL] [Abstract][Full Text] [Related]
36. Melatonin and Cancer Hallmarks. Talib WH Molecules; 2018 Feb; 23(3):. PubMed ID: 29495398 [TBL] [Abstract][Full Text] [Related]
37. The hallmarks of cancer are also the hallmarks of wound healing. MacCarthy-Morrogh L; Martin P Sci Signal; 2020 Sep; 13(648):. PubMed ID: 32900881 [TBL] [Abstract][Full Text] [Related]
38. Role of Y Box Protein-1 in cancer: As potential biomarker and novel therapeutic target. Maurya PK; Mishra A; Yadav BS; Singh S; Kumar P; Chaudhary A; Srivastava S; Murugesan SN; Mani A J Cancer; 2017; 8(10):1900-1907. PubMed ID: 28819388 [TBL] [Abstract][Full Text] [Related]
39. Sweetening the hallmarks of cancer: Galectins as multifunctional mediators of tumor progression. Girotti MR; Salatino M; Dalotto-Moreno T; Rabinovich GA J Exp Med; 2020 Feb; 217(2):. PubMed ID: 31873723 [TBL] [Abstract][Full Text] [Related]
40. The future of biology in driving the field of hyperthermia. Dewhirst MW; Lee CT; Ashcraft KA Int J Hyperthermia; 2016; 32(1):4-13. PubMed ID: 26850697 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]